Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways

CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene 2003-03, Vol.22 (9), p.1281-1293
Hauptverfasser: Weston, Claire R, Balmanno, Kathryn, Chalmers, Claire, Hadfield, Kathryn, Molton, Sarah A, Ley, Rebecca, Wagner, Erwin F, Cook, Simon J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1293
container_issue 9
container_start_page 1281
container_title Oncogene
container_volume 22
creator Weston, Claire R
Balmanno, Kathryn
Chalmers, Claire
Hadfield, Kathryn
Molton, Sarah A
Ley, Rebecca
Wagner, Erwin F
Cook, Simon J
description CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --> c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73082655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73082655</sourcerecordid><originalsourceid>FETCH-LOGICAL-p543-d4c5b7cee534f44484c98336ed486302aa05970551ed8e69a3500087dfb707213</originalsourceid><addsrcrecordid>eNo1UEtPwzAYywHExuAvoJy4VaR5NCm3MZUxOgGqdq_S5qta1BdNCvTf08G42LJkW7LP0JKEgnghZXSBLq19J4TIkNALtPBp4Csp2BKV69xVn9pVXYu7AkdJ7N9RnE3YQO10ogvPv48SPEA_gLVg8UPVYPj-VcdM1RroYYbW1dOxwZWAn19i3A34bcdi3GtXfunJXqHzQtcWrk-8QofH6LB58vav291mvfd6wZlneC4ymQMIxgvOueJ5qBgLwHAVMEK1JiKURAgfjIIg1EzMq5Q0RSaJpD5bodu_2n7oPkawLm0qm0Nd6xa60aaSEUUDIWbjzck4Zg2YtB-qRg9T-n8N-wHnz1yl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73082655</pqid></control><display><type>article</type><title>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</title><source>MEDLINE</source><source>SpringerLink Journals (MCLS)</source><source>EZB Free E-Journals</source><source>Springer Nature - Connect here FIRST to enable access</source><creator>Weston, Claire R ; Balmanno, Kathryn ; Chalmers, Claire ; Hadfield, Kathryn ; Molton, Sarah A ; Ley, Rebecca ; Wagner, Erwin F ; Cook, Simon J</creator><creatorcontrib>Weston, Claire R ; Balmanno, Kathryn ; Chalmers, Claire ; Hadfield, Kathryn ; Molton, Sarah A ; Ley, Rebecca ; Wagner, Erwin F ; Cook, Simon J</creatorcontrib><description>CC139 fibroblasts are one of several model systems in which the Raf --&gt; MEK --&gt; ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --&gt; c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --&gt; PDK --&gt; PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --&gt; c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.</description><identifier>ISSN: 0950-9232</identifier><identifier>PMID: 12618753</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Apoptosis - drug effects ; Apoptosis Regulatory Proteins ; bcl-2-Associated X Protein ; Bcl-2-Like Protein 11 ; Butadienes - pharmacology ; Carrier Proteins - biosynthesis ; Carrier Proteins - genetics ; Cell Line - drug effects ; Cell Line - metabolism ; Chromones - pharmacology ; Cricetinae ; Cricetulus ; Culture Media, Serum-Free - pharmacology ; Cycloheximide - pharmacology ; Cysteine Endopeptidases - pharmacology ; Cysteine Proteinase Inhibitors - pharmacology ; Dactinomycin - pharmacology ; Enzyme Activation - drug effects ; Enzyme Inhibitors - pharmacology ; Fibroblasts - metabolism ; JNK Mitogen-Activated Protein Kinases ; Lung ; Membrane Proteins ; Mitogen-Activated Protein Kinase 1 - antagonists &amp; inhibitors ; Mitogen-Activated Protein Kinase 1 - metabolism ; Mitogen-Activated Protein Kinase 3 ; Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors ; Mitogen-Activated Protein Kinases - metabolism ; Mitogen-Activated Protein Kinases - physiology ; Morpholines - pharmacology ; Nitriles - pharmacology ; Nucleic Acid Synthesis Inhibitors - pharmacology ; Phosphatidylinositol 3-Kinases - physiology ; Phosphoinositide-3 Kinase Inhibitors ; Protein Serine-Threonine Kinases - genetics ; Protein Serine-Threonine Kinases - metabolism ; Protein Structure, Tertiary ; Protein Synthesis Inhibitors - pharmacology ; Proto-Oncogene Proteins - metabolism ; Proto-Oncogene Proteins c-bcl-2 ; Proto-Oncogene Proteins c-raf - genetics ; Proto-Oncogene Proteins c-raf - physiology ; Recombinant Fusion Proteins - metabolism ; RNA, Messenger - biosynthesis ; RNA, Messenger - genetics ; Signal Transduction - drug effects ; Signal Transduction - physiology</subject><ispartof>Oncogene, 2003-03, Vol.22 (9), p.1281-1293</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12618753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weston, Claire R</creatorcontrib><creatorcontrib>Balmanno, Kathryn</creatorcontrib><creatorcontrib>Chalmers, Claire</creatorcontrib><creatorcontrib>Hadfield, Kathryn</creatorcontrib><creatorcontrib>Molton, Sarah A</creatorcontrib><creatorcontrib>Ley, Rebecca</creatorcontrib><creatorcontrib>Wagner, Erwin F</creatorcontrib><creatorcontrib>Cook, Simon J</creatorcontrib><title>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</title><title>Oncogene</title><addtitle>Oncogene</addtitle><description>CC139 fibroblasts are one of several model systems in which the Raf --&gt; MEK --&gt; ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --&gt; c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --&gt; PDK --&gt; PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --&gt; c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.</description><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis Regulatory Proteins</subject><subject>bcl-2-Associated X Protein</subject><subject>Bcl-2-Like Protein 11</subject><subject>Butadienes - pharmacology</subject><subject>Carrier Proteins - biosynthesis</subject><subject>Carrier Proteins - genetics</subject><subject>Cell Line - drug effects</subject><subject>Cell Line - metabolism</subject><subject>Chromones - pharmacology</subject><subject>Cricetinae</subject><subject>Cricetulus</subject><subject>Culture Media, Serum-Free - pharmacology</subject><subject>Cycloheximide - pharmacology</subject><subject>Cysteine Endopeptidases - pharmacology</subject><subject>Cysteine Proteinase Inhibitors - pharmacology</subject><subject>Dactinomycin - pharmacology</subject><subject>Enzyme Activation - drug effects</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fibroblasts - metabolism</subject><subject>JNK Mitogen-Activated Protein Kinases</subject><subject>Lung</subject><subject>Membrane Proteins</subject><subject>Mitogen-Activated Protein Kinase 1 - antagonists &amp; inhibitors</subject><subject>Mitogen-Activated Protein Kinase 1 - metabolism</subject><subject>Mitogen-Activated Protein Kinase 3</subject><subject>Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Mitogen-Activated Protein Kinases - physiology</subject><subject>Morpholines - pharmacology</subject><subject>Nitriles - pharmacology</subject><subject>Nucleic Acid Synthesis Inhibitors - pharmacology</subject><subject>Phosphatidylinositol 3-Kinases - physiology</subject><subject>Phosphoinositide-3 Kinase Inhibitors</subject><subject>Protein Serine-Threonine Kinases - genetics</subject><subject>Protein Serine-Threonine Kinases - metabolism</subject><subject>Protein Structure, Tertiary</subject><subject>Protein Synthesis Inhibitors - pharmacology</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Proto-Oncogene Proteins c-bcl-2</subject><subject>Proto-Oncogene Proteins c-raf - genetics</subject><subject>Proto-Oncogene Proteins c-raf - physiology</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>RNA, Messenger - biosynthesis</subject><subject>RNA, Messenger - genetics</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - physiology</subject><issn>0950-9232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UEtPwzAYywHExuAvoJy4VaR5NCm3MZUxOgGqdq_S5qta1BdNCvTf08G42LJkW7LP0JKEgnghZXSBLq19J4TIkNALtPBp4Csp2BKV69xVn9pVXYu7AkdJ7N9RnE3YQO10ogvPv48SPEA_gLVg8UPVYPj-VcdM1RroYYbW1dOxwZWAn19i3A34bcdi3GtXfunJXqHzQtcWrk-8QofH6LB58vav291mvfd6wZlneC4ymQMIxgvOueJ5qBgLwHAVMEK1JiKURAgfjIIg1EzMq5Q0RSaJpD5bodu_2n7oPkawLm0qm0Nd6xa60aaSEUUDIWbjzck4Zg2YtB-qRg9T-n8N-wHnz1yl</recordid><startdate>20030306</startdate><enddate>20030306</enddate><creator>Weston, Claire R</creator><creator>Balmanno, Kathryn</creator><creator>Chalmers, Claire</creator><creator>Hadfield, Kathryn</creator><creator>Molton, Sarah A</creator><creator>Ley, Rebecca</creator><creator>Wagner, Erwin F</creator><creator>Cook, Simon J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20030306</creationdate><title>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</title><author>Weston, Claire R ; Balmanno, Kathryn ; Chalmers, Claire ; Hadfield, Kathryn ; Molton, Sarah A ; Ley, Rebecca ; Wagner, Erwin F ; Cook, Simon J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p543-d4c5b7cee534f44484c98336ed486302aa05970551ed8e69a3500087dfb707213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis Regulatory Proteins</topic><topic>bcl-2-Associated X Protein</topic><topic>Bcl-2-Like Protein 11</topic><topic>Butadienes - pharmacology</topic><topic>Carrier Proteins - biosynthesis</topic><topic>Carrier Proteins - genetics</topic><topic>Cell Line - drug effects</topic><topic>Cell Line - metabolism</topic><topic>Chromones - pharmacology</topic><topic>Cricetinae</topic><topic>Cricetulus</topic><topic>Culture Media, Serum-Free - pharmacology</topic><topic>Cycloheximide - pharmacology</topic><topic>Cysteine Endopeptidases - pharmacology</topic><topic>Cysteine Proteinase Inhibitors - pharmacology</topic><topic>Dactinomycin - pharmacology</topic><topic>Enzyme Activation - drug effects</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fibroblasts - metabolism</topic><topic>JNK Mitogen-Activated Protein Kinases</topic><topic>Lung</topic><topic>Membrane Proteins</topic><topic>Mitogen-Activated Protein Kinase 1 - antagonists &amp; inhibitors</topic><topic>Mitogen-Activated Protein Kinase 1 - metabolism</topic><topic>Mitogen-Activated Protein Kinase 3</topic><topic>Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Mitogen-Activated Protein Kinases - physiology</topic><topic>Morpholines - pharmacology</topic><topic>Nitriles - pharmacology</topic><topic>Nucleic Acid Synthesis Inhibitors - pharmacology</topic><topic>Phosphatidylinositol 3-Kinases - physiology</topic><topic>Phosphoinositide-3 Kinase Inhibitors</topic><topic>Protein Serine-Threonine Kinases - genetics</topic><topic>Protein Serine-Threonine Kinases - metabolism</topic><topic>Protein Structure, Tertiary</topic><topic>Protein Synthesis Inhibitors - pharmacology</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Proto-Oncogene Proteins c-bcl-2</topic><topic>Proto-Oncogene Proteins c-raf - genetics</topic><topic>Proto-Oncogene Proteins c-raf - physiology</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>RNA, Messenger - biosynthesis</topic><topic>RNA, Messenger - genetics</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weston, Claire R</creatorcontrib><creatorcontrib>Balmanno, Kathryn</creatorcontrib><creatorcontrib>Chalmers, Claire</creatorcontrib><creatorcontrib>Hadfield, Kathryn</creatorcontrib><creatorcontrib>Molton, Sarah A</creatorcontrib><creatorcontrib>Ley, Rebecca</creatorcontrib><creatorcontrib>Wagner, Erwin F</creatorcontrib><creatorcontrib>Cook, Simon J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Oncogene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weston, Claire R</au><au>Balmanno, Kathryn</au><au>Chalmers, Claire</au><au>Hadfield, Kathryn</au><au>Molton, Sarah A</au><au>Ley, Rebecca</au><au>Wagner, Erwin F</au><au>Cook, Simon J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways</atitle><jtitle>Oncogene</jtitle><addtitle>Oncogene</addtitle><date>2003-03-06</date><risdate>2003</risdate><volume>22</volume><issue>9</issue><spage>1281</spage><epage>1293</epage><pages>1281-1293</pages><issn>0950-9232</issn><abstract>CC139 fibroblasts are one of several model systems in which the Raf --&gt; MEK --&gt; ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic 'BH3-only' member of the Bcl-2 protein family. Bim(EL) expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK --&gt; c-Jun pathway was neither necessary nor sufficient to induce Bim(EL) expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of Bim(EL). Furthermore, selective activation of the ERK1/2 pathway by deltaRaf-1:ER* substantially reduced Bim(EL) expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of deltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --&gt; PDK --&gt; PKB pathway. Thus, serum withdrawal-induced expression of Bim(EL) occurs independently of the JNK --&gt; c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.</abstract><cop>England</cop><pmid>12618753</pmid><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0950-9232
ispartof Oncogene, 2003-03, Vol.22 (9), p.1281-1293
issn 0950-9232
language eng
recordid cdi_proquest_miscellaneous_73082655
source MEDLINE; SpringerLink Journals (MCLS); EZB Free E-Journals; Springer Nature - Connect here FIRST to enable access
subjects Animals
Apoptosis - drug effects
Apoptosis Regulatory Proteins
bcl-2-Associated X Protein
Bcl-2-Like Protein 11
Butadienes - pharmacology
Carrier Proteins - biosynthesis
Carrier Proteins - genetics
Cell Line - drug effects
Cell Line - metabolism
Chromones - pharmacology
Cricetinae
Cricetulus
Culture Media, Serum-Free - pharmacology
Cycloheximide - pharmacology
Cysteine Endopeptidases - pharmacology
Cysteine Proteinase Inhibitors - pharmacology
Dactinomycin - pharmacology
Enzyme Activation - drug effects
Enzyme Inhibitors - pharmacology
Fibroblasts - metabolism
JNK Mitogen-Activated Protein Kinases
Lung
Membrane Proteins
Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors
Mitogen-Activated Protein Kinase 1 - metabolism
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinases - antagonists & inhibitors
Mitogen-Activated Protein Kinases - metabolism
Mitogen-Activated Protein Kinases - physiology
Morpholines - pharmacology
Nitriles - pharmacology
Nucleic Acid Synthesis Inhibitors - pharmacology
Phosphatidylinositol 3-Kinases - physiology
Phosphoinositide-3 Kinase Inhibitors
Protein Serine-Threonine Kinases - genetics
Protein Serine-Threonine Kinases - metabolism
Protein Structure, Tertiary
Protein Synthesis Inhibitors - pharmacology
Proto-Oncogene Proteins - metabolism
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-raf - genetics
Proto-Oncogene Proteins c-raf - physiology
Recombinant Fusion Proteins - metabolism
RNA, Messenger - biosynthesis
RNA, Messenger - genetics
Signal Transduction - drug effects
Signal Transduction - physiology
title Activation of ERK1/2 by deltaRaf-1:ER represses Bim expression independently of the JNK or PI3K pathways
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T16%3A33%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20ERK1/2%20by%20deltaRaf-1:ER%20represses%20Bim%20expression%20independently%20of%20the%20JNK%20or%20PI3K%20pathways&rft.jtitle=Oncogene&rft.au=Weston,%20Claire%20R&rft.date=2003-03-06&rft.volume=22&rft.issue=9&rft.spage=1281&rft.epage=1293&rft.pages=1281-1293&rft.issn=0950-9232&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E73082655%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73082655&rft_id=info:pmid/12618753&rfr_iscdi=true